Noticias de la sanidad estadounidense

1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

Fulgent Genetics (NASDAQ: FLGT) has been a fascinating company to watch over the past few years. Since the end of 2019, its shares are up 187% compared to the S&P 500 ‘s 23%. While that’s an impressive market beat, there was a point in early 2021 when Fulgent’s stock was up over 1,300%.

This wild stock movement was spurred on by incredible revenue growth due to Fulgent’s ability to pivot to providing COVID-19 tests early in 2020. That made the company a prime example of the pandemic-induced mania the stock market saw over the past few years.

As the pandemic has slowly subsided, Fulgent has continued to put up strong results, but the most recent quarter raised a concern I think investors should be aware of now. Let’s take a look.

Seguir leyendo

Para más detalles, véase:

1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

Artículos relacionados

Botón de vuelta al principio